A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers

Trial Profile

A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Selumetinib (Primary) ; Vistusertib (Primary)
  • Indications Breast cancer; Colorectal cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms TORCMEK
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results assessing optimal doses and schedule of vistusertib and selumetinib when given in combination, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Dec 2015 Accrual to date is 10% as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top